Compare F5 Inc (FFIV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Twist Bioscience Corp — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: F5 Inc is far larger — about 2.6× Twist Bioscience Corp's market cap, and F5 Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Twist Bioscience Corp for 27 Days on average.
| FFIV | TWST | |
|---|---|---|
Market Cap | $26.14B | $10.08B |
Volume | 503,146 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $479.83 | $205.00 |
52-Week Low | $223.99 | $25.45 |
Typical Hold Time | 38 Days | 27 Days |
Enterprise Value | $24.78B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue and net income have shown steady growth, reaching $3.09 billion and $692.38 million in 2025, respectively. Positive sentiment is fueled by recent strategic partnerships and industry recognitions, such as being named a Leader in the IDC MarketScape for WAAP platforms.
The stock's valuation appears elevated with a P/E of 36.78 and P/S of 8.07, posing a risk if growth moderates. Analyst consensus is mixed with a $416.60 price target below the current price, suggesting caution despite a majority Hold rating. Key investment opportunities include continued execution on AI security initiatives, while risks involve competitive pressures and reliance on enterprise spending. The stock's proximity to resistance at $468 warrants monitoring for breakout or pullback signals.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
